sec filing
GA
NASDAQ · GALT
Galectin Therapeutics Inc.
Healthcare · Biotechnology
$3.90
Up+$0.03 (+0.64%)
Updated Sep 11, 2026, 2:25 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 369.89M
- P/E ratio
- -9.89
- Dividend yield
- 0.00%
- 52-week range
- $2.03 – $5.55
- Volume
- 253.05K
- Avg. volume
- 407.75K
Price performance
GALT price history
1M range · 20 trading sessions · Daily adjusted prices
GALT closed at $3.90 after 20 trading sessions, up 10.48% for the selected period.
- Last close
- $3.90
- Period change
- +10.48%
- Period low
- $3.44
- Period high
- $4.61
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $4.00 | $4.0499 | $3.84 | $3.90 | 253.05K |
| Sep 9, 2026 | $4.13 | $4.34 | $4.035 | $4.05 | 515.69K |
| Sep 8, 2026 | $4.60 | $4.65 | $4.10 | $4.14 | 393.42K |
| Sep 4, 2026 | $4.33 | $4.72 | $4.33 | $4.61 | 473.55K |
| Sep 3, 2026 | $4.50 | $4.60 | $4.224 | $4.35 | 244.15K |
| Sep 2, 2026 | $4.19 | $4.53 | $4.19 | $4.48 | 460.7K |
| Sep 1, 2026 | $3.91 | $4.385 | $3.91 | $4.17 | 479.58K |
| Aug 31, 2026 | $4.02 | $4.05 | $3.91 | $3.95 | 229.71K |
| Aug 28, 2026 | $4.14 | $4.20 | $3.95 | $4.02 | 271.19K |
| Aug 27, 2026 | $4.15 | $4.45 | $4.04 | $4.14 | 345.23K |
| Aug 26, 2026 | $3.95 | $4.205 | $3.92 | $4.15 | 291.11K |
| Aug 25, 2026 | $4.07 | $4.19 | $3.845 | $3.99 | 194.72K |
| Aug 24, 2026 | $3.68 | $3.97 | $3.58 | $3.88 | 227.96K |
| Aug 21, 2026 | $3.62 | $3.74 | $3.5871 | $3.68 | 174.93K |
| Aug 20, 2026 | $3.67 | $3.7493 | $3.44 | $3.57 | 313.11K |
| Aug 19, 2026 | $3.54 | $3.77 | $3.54 | $3.67 | 353.79K |
| Aug 18, 2026 | $3.47 | $3.55 | $3.325 | $3.52 | 317.94K |
| Aug 17, 2026 | $3.36 | $3.67 | $3.31 | $3.51 | 300.05K |
| Aug 14, 2026 | $3.50 | $3.5462 | $3.20 | $3.44 | 388.21K |
| Aug 13, 2026 | $3.16 | $3.56 | $3.16 | $3.53 | 585.3K |
Latest GALT news
The latest Smart Investors Daily articles mentioning GALT.
Stock researchCompany · Earnings
Loading stock research…